Keating Financial Advisory Services’s Mineralys Therapeutics MLYS Stock Holding History

Keating Financial Advisory Services’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.12K	Buy	+226	New	+$6.63K	﹤0.01%	1333

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Keating Financial Advisory Services's MLYS Position: Q1 2026 in Review

Keating Financial Advisory Services opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 226 shares worth $6.12K. The stake represents ﹤0.01% of the portfolio and ranks #1333 among its holdings.

214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Keating Financial Advisory Services held 226 shares of Mineralys Therapeutics worth $6.12K as of Q1 2026.
Mineralys Therapeutics was a new Keating Financial Advisory Services position in Q1 2026.
Mineralys Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #1333 holding.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.